CD274 and neoplasm: Treatment with murine surrogate of CEA-TCB (muCEA-TCB) and of anti-PD-L1 blocking antibody (muPD-L1) led to more rapid, more pronounced and sustained tumor growth inhibition as compared to the respective monotherapy treatment groups (Figure 5A).